Dr Reddy’s Enters OTC Eyecare Space
Executive Summary
Dr Reddy’s has announced the launch of its OTC versions of Pataday olopatadine solution in the US. The firm’s entry into the OTC eyecare space follows other OTC launches of rivals to Voltaren and Nicorette earlier this year.
You may also be interested in...
Dr Reddy's Adds To OTC Portfolio With Glenmark Deal
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Dr Reddy's Strengthens Russian OTC Portfolio Through Glenmark Deal
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Dr Reddy’s And Perrigo Capitalize On Voltaren Switch
Seven months after GlaxoSmithKline’s Voltaren Arthritis Pain (diclofenac sodium) 1% topical gel was switched to non-prescription status in the US, two companies have begun shipping equivalent OTC versions to retailers.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to HBW Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: